Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACAD 
ACADIA Pharmaceuticals Inc (ACAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ACAD (3-star) is a STRONG-BUY. BUY since 64 days. Profits (42.95%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $29.95
1 Year Target Price $29.95
| 7 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.12% | Avg. Invested days 50 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.14B USD | Price to earnings Ratio 18.44 | 1Y Target Price 29.95 |
Price to earnings Ratio 18.44 | 1Y Target Price 29.95 | ||
Volume (30-day avg) 20 | Beta 0.7 | 52 Weeks Range 13.40 - 25.88 | Updated Date 08/15/2025 |
52 Weeks Range 13.40 - 25.88 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.14 | Actual 0.16 |
Profitability
Profit Margin 21.8% | Operating Margin (TTM) 12.24% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 33.18% |
Valuation
Trailing PE 18.44 | Forward PE 53.19 | Enterprise Value 3432808756 | Price to Sales(TTM) 4.06 |
Enterprise Value 3432808756 | Price to Sales(TTM) 4.06 | ||
Enterprise Value to Revenue 3.37 | Enterprise Value to EBITDA 33.02 | Shares Outstanding 168712000 | Shares Floating 116171860 |
Shares Outstanding 168712000 | Shares Floating 116171860 | ||
Percent Insiders 0.57 | Percent Institutions 105.24 |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc
Company Overview
History and Background
ACADIA Pharmaceuticals Inc. was founded in 1993. Initially focused on discovering new drugs for central nervous system disorders, ACADIA's significant milestone was the FDA approval of NUPLAZID (pimavanserin) for Parkinson's disease psychosis in 2016. The company has since expanded its focus to other neurological conditions.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for neurological disorders such as Parkinson's disease psychosis and Rett syndrome.
- Central Nervous System: Development of treatments addressing central nervous system disorders.
Leadership and Structure
The CEO is Steve Davis. The organizational structure includes departments for research and development, commercial operations, medical affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- NUPLAZID (pimavanserin): NUPLAZID is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. This product had 2023 revenue of $596.6 million. Competitors include generic antipsychotics used off-label.
- DAYBUE (trofinetide): DAYBUE is approved for the treatment of Rett syndrome. It was launched in April 2023. Estimated annual TAM is over $500M. Competitors include symptomatic treatments for Rett syndrome.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurological and psychiatric disorders is characterized by high research and development costs, stringent regulatory requirements, and significant unmet medical needs.
Positioning
ACADIA is positioned as a specialty pharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders with high unmet needs. Its competitive advantage lies in its focus on specific, underserved patient populations and its expertise in developing novel therapies.
Total Addressable Market (TAM)
The total addressable market for ACADIA's key products is significant, estimated to be in the billions of dollars. NUPLAZID addresses a substantial portion of Parkinson's disease psychosis market, and DAYBUE taps into the previously underserved Rett syndrome market. ACADIA is positioned to capture significant share.
Upturn SWOT Analysis
Strengths
- FDA-approved product (NUPLAZID)
- Specialized focus on CNS disorders
- Established commercial infrastructure
- Strong intellectual property portfolio
- Recently FDA-Approved DAYBUE
Weaknesses
- Reliance on a limited number of products
- Risk of clinical trial failures
- Regulatory risks
- Commercial dependence on NUPLAZID
- Need to expand product pipeline.
Opportunities
- Expansion of NUPLAZID's label to other indications
- Development of new therapies for CNS disorders
- Strategic partnerships and acquisitions
- Geographic expansion
- Increase awareness and diagnosis rates for Rett syndrome to boost DAYBUE sales
Threats
- Competition from other pharmaceutical companies
- Generic entry of NUPLAZID
- Changes in reimbursement policies
- Unfavorable clinical trial results
- Adverse events associated with products.
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- LLY
Competitive Landscape
ACADIA's competitive advantage lies in its first-mover advantage in Parkinson's disease psychosis with NUPLAZID and Rett Syndrome with DAYBUE. However, it faces competition from generic antipsychotics and other companies developing therapies for CNS disorders.
Major Acquisitions
Neuren Pharmaceuticals Limited
- Year: 2018
- Acquisition Price (USD millions): 20
- Strategic Rationale: Licensed exclusive North American rights to trofinetide, now DAYBUE, expanding ACADIA's CNS pipeline.
Growth Trajectory and Initiatives
Historical Growth: ACADIA's growth has been driven by the commercial success of NUPLAZID. The company has also invested in R&D to expand its product pipeline.
Future Projections: Analyst projections suggest continued revenue growth driven by NUPLAZID and DAYBUE, but profitability may take several years as ACADIA invests in R&D and commercialization.
Recent Initiatives: Recent initiatives include the launch of DAYBUE, expansion of NUPLAZID commercialization, and ongoing clinical trials for new indications and pipeline development.
Summary
ACADIA Pharmaceuticals is a specialty pharmaceutical company with an FDA-approved product in NUPLAZID, but is not profitable due to ongoing R&D. It has a new product approved to treat Rett Syndrome called DAYBUE. The company needs to watch out for increased competition and failure of its pipeline drugs. Acadia is positioned to potentially capture significant share with DAYBUE.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ACADIA Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com | ||
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.